Kunbo Medical-B (02216) plans to acquire 157,800 Series B preferred shares of Valgen Holding Corporation for $15 million

According to Zhitong Finance App, Kunbo Medical-B (02216) announced that on December 29, 2025, Broncus China Holding Corporation, a wholly-owned subsidiary of the company, plans to acquire 157,800 B-series preferred shares of Valgen Holding Corporation from Qiming Healthcare (Hong Kong) Co., Ltd., accounting for 1.05% of the target company's outstanding shares based on comprehensive dilution and conversion criteria as of the date of this announcement, at a total cost of US$15 million. Target Group is mainly engaged in providing system solutions for diseases such as mitral valve reflux and tricuspid valve reflux. ^{Its products include the mitral valve repair device DragonFly™ (transfemoral route) and the tricuspid valve repair device DragonFly-T TM.}

Given the similarities and connections between structural heart disease and lung disease, the Board believes that the acquisition provides a valuable opportunity for the Group to achieve comprehensive diagnosis and treatment of cardiopulmonary diseases. With the company's expertise in chronic obstructive pulmonary disease, cooperation with the target group will enable the group to lay a solid foundation for the establishment of a comprehensive diagnosis and treatment platform for cardiopulmonary diseases. Furthermore, since treatment of structural heart disease and lung disease involves interventional therapy, the acquisition also provided the Group with an opportunity to enhance its R&D capabilities and apply its structural heart disease treatment technology to the treatment of lung diseases, and vice versa.